Detalhe da pesquisa
1.
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
Lancet Oncol
; 22(9): 1312-1321, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34416158
2.
Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Pediatr Blood Cancer
; 66(8): e27819, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-31115156
3.
Scaling up and implementing the digital Survivorship Passport tool in routine clinical care - The European multidisciplinary PanCareSurPass project.
Eur J Cancer
; 202: 114029, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38513384
4.
European recommendations for short-term surveillance of health problems in childhood, adolescent and young adult cancer survivors from the end of treatment to 5 years after diagnosis: a PanCare guideline.
J Cancer Surviv
; 2023 Dec 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38048011
5.
Barriers and facilitators to implementation of the interoperable Survivorship Passport (SurPass) v2.0 in 6 European countries: a PanCareSurPass online survey study.
J Cancer Surviv
; 2023 Feb 20.
Artigo
Inglês
| MEDLINE | ID: mdl-36808389
6.
Correction: Barriers and facilitators to the implementation of a new European eHealth solution (SurPass v2.0): the PanCareSurPass Open Space study.
J Cancer Surviv
; 2024 Mar 11.
Artigo
Inglês
| MEDLINE | ID: mdl-38466480